Page last updated: 2024-12-05

protoporphyrin ix

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Protoporphyrin IX (PPIX) is a porphyrin molecule that serves as a precursor in the biosynthesis of heme, a crucial component of hemoglobin, myoglobin, and various enzymes. Its synthesis involves a complex multi-step pathway, beginning with the condensation of succinyl CoA and glycine to form δ-aminolevulinate. This molecule undergoes a series of enzymatic reactions, including decarboxylation, condensation, and oxidation, leading to the formation of protoporphyrin IX. PPIX readily binds iron ions, forming heme, which is then incorporated into proteins.

PPIX is also a key molecule in the diagnosis and treatment of various diseases. Accumulation of PPIX in erythrocytes can lead to porphyrias, a group of genetic disorders characterized by impaired heme biosynthesis. In the clinical setting, PPIX accumulation can be visualized using fluorescence imaging techniques, allowing for early diagnosis and monitoring of porphyrias.

Furthermore, PPIX has been explored for its potential therapeutic applications, particularly in photodynamic therapy (PDT). PDT utilizes the ability of PPIX to absorb light energy and generate reactive oxygen species (ROS), which can induce cell death. PDT has demonstrated promising results in treating various cancers, including skin, bladder, and lung cancers.

The study of PPIX is essential for understanding the intricate mechanisms of heme biosynthesis, the diagnosis and management of porphyrias, and the development of novel therapeutic strategies based on its photodynamic properties. '

protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4971
CHEMBL ID267548
CHEMBL ID1325592
CHEMBL ID1907972
CHEMBL ID1907974
CHEMBL ID4463327
CHEMBL ID1618319
CHEBI ID15430
SCHEMBL ID805850
SCHEMBL ID25719
SCHEMBL ID3287054
SCHEMBL ID14552654
MeSH IDM0090624

Synonyms (132)

Synonym
smr000127405
MLS001074731 ,
ppix
ooporphyrin
21h,18-dipropanoic acid, 7,12-diethenyl-3,8,13,17-tetramethyl-
2, 3,8,13,17-tetramethyl-7,12-divinyl-
nsc-2632
nsc2632 ,
3,7,12,17-tetramethyl-8,13-divinylporphyrin-2,18-dipropanoic acid
7,12-diethenyl-3,8,13,17-tetramethylporphyrin-2,18-dipropanoic acid
3,3'-(3,7,12,17-tetramethyl-8,13-divinyl-21h,23h-porphine-2,18-diyl)-bis-propionic acid
h2ppix
CHEBI:15430 ,
kammerer's prophyrin
DIVK1C_000074
KBIO1_000074
SDCCGMLS-0066712.P001
EU-0100973
protoporphyrin ix, >=95%
SPECTRUM_001300
NCGC00015844-01
IDI1_000074
LOPAC0_000973
3-[(1z,4z,9z,15z)-18-(2-carboxyethyl)-3,7,12,17-tetramethyl-8,13-divinyl-21,23-dihydroporphyrin-2-yl]propanoic acid
3,7,12,17-tetramethyl-8,13-divinyl-2,18-porphinedipropionic acid
protoporpyrin ix
kammerer's porphyrin
21h,23h-porphine-2,18-dipropanoic acid, 7,12-diethenyl-3,8,13,17-tetramethyl-
2,18-porphinedipropionic acid, 3,8,13,17-tetramethyl-7,12-divinyl- (8ci)
3,3'-(3,7,12,17-tetramethyl-8,13-divinylporphine-2,18-diyl)di(propionic acid)
2,18-porphinedipropionic acid, 3,8,13,17-tetramethyl-7,12-divinyl-
porphyrinogen ix
553-12-8
C02191
protoporphyrin
protoporphyrin ix
DB02285
SPECTRUM5_001303
NCGC00094273-02
NCGC00094273-03
KBIOGR_000718
KBIOSS_001780
KBIO2_004348
KBIO3_002400
KBIO2_001780
KBIO2_006916
SPBIO_001171
SPECTRUM4_000419
SPECTRUM2_001016
SPECTRUM3_001440
NINDS_000074
SPECTRUM1501111
BSPBIO_003180
nsc 2632
NCGC00162303-01
protoporphyrin ix disodium
NCGC00094273-01
einecs 209-033-7
NCGC00015844-02
P 8293
NCGC00015844-07
CHEMBL267548 ,
HMS500D16
HMS1921F05
3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid
NCGC00185010-01
SR-01000763747-3
sr-01000763747
HMS3263C07
nsc-757839
pharmakon1600-01501111
nsc757839
HMS2271B12
CCG-39673
NCGC00015844-08
NCGC00015844-04
NCGC00015844-03
NCGC00015844-05
unii-c2k325s808
c2k325s808 ,
LP00973
protoporphyrin ix [mi]
protoporphyrin [who-dd]
1,3,5,8-tetramethyl-2,4-divinylporphine-6,7-dipropionate
CHEMBL1325592
SCHEMBL805850
SCHEMBL25719
CHEMBL1907972
CS-4849
NCGC00261658-01
tox21_500973
SCHEMBL3287054
protoporphyrinix
DTXSID4048353
CHEMBL1907974
bdbm51757
3-[18-(2-carboxyethyl)-3,7,12,17-tetramethyl-8,13-divinyl-22,23-dihydroporphin-2-yl]propionic acid
3-[8,13-bis(ethenyl)-18-(3-hydroxy-3-oxopropyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid
3-[(1z,4z,9z,15z)-18-(2-carboxy-ethyl)-3,7,12,17-tetramethyl-8,13-divinyl-porphyrin-2-yl]-propionic acid
cid_4971
SCHEMBL14552654
OXTIQTUKEUGAPP-UJJXFSCMSA-N
HY-B1247
AB00052204_02
FT-0696783
AKOS027320494
sr-01000076084
SR-01000076084-5
CHEMBL4463327
SR-01000076084-4
SR-01000076084-1
SBI-0050946.P003
KSFOVUSSGSKXFI-UHFFFAOYSA-N
3,3'-(3,7,12,17-tetramethyl-8,13-divinyl-21h,23h-porphine-2,18-diyl)-bis-propionate
protoporphyrin-ix
3,3'-(3,7,12,17-tetramethyl-8,13-divinylporphine-2,18-diyl)di
3,3'-(3,8,13,17-tetramethyl-7,12-divinylporphyrin-2,18-diyl)dipropionic acid
3,3'-(7,12-diethenyl-3,8,13,17-tetramethylporphyrin-2,18-diyl)dipropanoic acid
Q619815
FEDYMSUPMFCVOD-UHFFFAOYSA-N
AS-17461
BRD-K26813314-001-04-4
SDCCGSBI-0050946.P004
NCGC00015844-12
C75594
21h,23h-porphine-2,18-dipropanoic acid,7,12-diethenyl-3,8,13,17-tetramethyl-
protoporphyrin ix [mesh: protoporphyrin ix]
protoporphyrin-9
CHEMBL1618319
bdbm50523755
A870226
3-[18-(2-carboxyethyl)-3,8,13,17-tetramethyl-7,12-divinyl-21,23-dihydroporphyrin-2-yl]propanoic acid

Research Excerpts

Overview

Protoporphyrin IX (PpIX) is an intermediate in the heme biosynthesis pathway. It cannot be used directly in photodynamic therapy due to its aggregation in physiological environment.

ExcerptReferenceRelevance
"Protoporphyrin IX (PpIX), which is an efficient photosensitive agent, cannot be used directly in photodynamic therapy due to its aggregation in physiological environment. "( Synthesis and photodynamic efficacy of water-soluble protoporphyrin IX homologue with mPEG550.
Basoglu, H; Degirmencioglu, I; Eyupoglu, FC, 2021
)
2.31
"Protoporphyrin IX (PPIX) is an intermediate in the heme biosynthesis pathway. "( Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics.
Anderson, KE; Hussain, Z; Ma, X; Qi, Q; Zhu, J, 2023
)
3.8
"Protoporphyrin IX (PpIX) is an endogenous photosensitizer (PS) widely used, obtained by the administration of precursors such as aminolevulinic acid and methyl aminolevulinate."( Use of dermograph for improvement of PpIX precursor's delivery in photodynamic therapy: Experimental and clinical pilot studies.
Bagnato, VS; Fortunato, TC; Pratavieira, S; Requena, MB; Russignoli, PE; Salvio, AG; Vollet-Filho, JD, 2020
)
1.28
"Protoporphyrin IX (PpIX) is a precursor of heme synthesis and is known to be an active photosensitizer and precursor of photosensitizers applied in photodynamic therapy (PDT) and photodynamic diagnostics (PDD). "( Comparative study of phototoxicity of protoporphyrin IX synthetic and extracted from ssp Rattus novergicus albinus rats toward murine melanoma cells.
Borissevitch, I; Ferreira, LP; Nicola, EMD; Reis, ER, 2018
)
2.19
"Protoporphyrin IX (PPIX) is a photodynamic therapy (PDT) agent for the treatment of various types of cancer. "( Characterization of Protoporphyrin IX Species in Vitro Using Fluorescence Spectroscopy and Polar Plot Analysis.
Lee, SH; Teng, KW, 2019
)
2.28
"Protoporphyrin IX (PpIX) is an effective hematoporphyrin derivative, widely adopted in photodynamic therapy (PDT) and sonodynamic therapy (SDT). "( Comparison of protoporphyrin IX produced cell proliferation inhibition between human breast cancer MCF-7 and MDA-MB-231 cells.
Chen, Y; Feng, X; Li, L; Liu, Q; Wang, P; Wang, X, 2014
)
2.21
"Protoporphyrin IX (PpIX) is a well-known photosensitizer that has great potential for use in photodynamic therapy (PDT). "( Protoporphyrin IX-loaded magnetoliposomes as a potential drug delivery system for photodynamic therapy: Fabrication, characterization and in vitro study.
Basoglu, H; Bilgin, MD; Demir, MM, 2016
)
3.32
"Protoporphyrin IX is an activator of soluble guanylate cyclase (sGC), but its role as an endogenous regulator of vascular function through cGMP has not been previously reported. "( Protoporphyrin IX generation from delta-aminolevulinic acid elicits pulmonary artery relaxation and soluble guanylate cyclase activation.
Abraham, NG; Ahmad, M; Chow, JL; Gupte, SA; Mingone, CJ; Wolin, MS, 2006
)
3.22
"Protoporphyrin IX (PpIX) is an endogenous photosensitizer commonly used in photodynamic therapy. "( Randomized control trial of fluorescence-guided surgical excision of nonmelanotic cutaneous malignancies.
Brandt, MG; Jordan, K; Moore, CC, 2007
)
1.78
"Protoporphyrin IX is an important kind of organic compound for vital movement, and can be used as the sign of tumour blood. "( [Fluorescence spectrum analysis system for protoporphyrin IX in serum based on wavelet transform].
Liu, Y; Lu, J; Luo, XS; Ni, XW; Shen, ZH; Yang, HP; Zhu, DM, 2007
)
2.05
"Protoporphyrin IX (PpIX) is a porphyrin derivative that is accumulated in cancerous tissue in consequence of the tumor-specific metabolic alterations. "( Correlation between autofluorescence intensity and tumor area in mice bearing renal cell carcinoma.
Bellini, MH; Courrol, LC; Coutinho, EL; Rodrigues de Oliveira Silva, F; Schor, N; Vieira Júnior, ND, 2008
)
1.79
"Protoporphyrin IX itself is a potential photosensitizer that can be used for laser light-induced fluorescence diagnosis."( Local 5-aminolevulinic acid application for laser light-induced fluorescence diagnosis of early staged colon cancer in rats.
Böhm, J; Gahlen, J; Herfarth, C; Holle, R; Pressmar, J; Stern, J, 2000
)
1.03

Effects

Protoporphyrin IX (PpIX) has wide applications in photodynamic diagnosis and photodynamic therapy (PDT) in many human diseases. It has an additive cytotoxic effect in the presence of blue light, suggesting that this photosensitizer is capable of mediating blue-light-induced retinal pigment epithelial damage.

ExcerptReferenceRelevance
"Protoporphyrin IX has an additive cytotoxic effect in the presence of blue light, suggesting that this photosensitizer is capable of mediating blue-light-induced retinal pigment epithelial damage."( Photosensitization of retinal pigment epithelium by protoporphyrin IX.
Bynoe, LA; Del Priore, LV; Hornbeck, R, 1998
)
1.27
"The protoporphyrin IX in eggshells has also been analysed in order to explore the use of this pigment as a biomarker."( Organochlorine pesticides and polychlorinated biphenyls in common kestrel eggs from the Canary Islands: Spatiotemporal variations and effects on eggshell and reproduction.
Buck, A; Camarero, PR; Carrillo-Hidalgo, J; Mateo, R, 2020
)
1.04
"Protoporphyrin IX (PpIX) has been used as a sensitizer in photodynamic therapy (PDT) as well as in sonodynamic therapy (SDT). "( The spectroscopy analyses of PpIX by ultrasound irradiation and its sonotoxicity in vitro.
Gao, K; Liu, Q; Song, M; Wang, P; Wang, X; Zhang, K, 2013
)
1.83
"Protoporphyrin IX (PPIX) has been used for photodynamic therapy."( Increase of miR-199a-5p by protoporphyrin IX, a photocatalyzer, directly inhibits E2F3, sensitizing mesenchymal tumor cells to anti-cancer agents.
Heo, MJ; Kim, SG; Lee, CG; Lee, JM; Yang, YM, 2015
)
1.44
"Protoporphyrin IX (PpIX) has wide applications in photodynamic diagnosis and photodynamic therapy (PDT) in many human diseases. "( Enhanced cellular uptake of protoporphyrine IX/linolenic acid-conjugated spherical nanohybrids for photodynamic therapy.
Kim, YJ; Lee, HI, 2016
)
1.88
"Protoporphyrin IX has been used as an efficient sensitizer in photodynamic diagnosis, photodynamic therapy, and sonodynamic therapy. "( Over expression of 5-aminolevulinic acid synthase 2 increased protoporphyrin IX in nonerythroid cells.
Diao, Y; He, Q; Huang, H; Liang, H; Nakajima, O; Peng, Y; Wang, W; Zhang, L; Zhou, L; Zou, J, 2017
)
2.14
"Protoporphyrin IX (PPIX) has two flexible propionic acid tails and is one of the most common amphiphilic porphyrins."( Stacking Geometries of Early Protoporphyrin IX Aggregates Revealed by Gas-Phase Infrared Spectroscopy.
Gewinner, S; Jang, J; Schöllkopf, W; Seo, J; von Helden, G; Warnke, S, 2016
)
1.45
"Protoporphyrin IX has an additive cytotoxic effect in the presence of blue light, suggesting that this photosensitizer is capable of mediating blue-light-induced retinal pigment epithelial damage."( Photosensitization of retinal pigment epithelium by protoporphyrin IX.
Bynoe, LA; Del Priore, LV; Hornbeck, R, 1998
)
1.27

Toxicity

ExcerptReferenceRelevance
" We compared experimentally the photodynamic effect (light-toxic) and the side effect (dark-toxic) of the clinically attractive photosensitizers 5-aminolevulinic acid (ALA) and protoporphyrin IX (PP IX)."( Light irradiation increases embryotoxicity of photodynamic therapy sensitizers (5-aminolevulinic acid and protoporphyrin IX) in chick embryos.
Klepácek, I; Peterka, M,
)
0.54
" This method of enhancement was safely applied to a clinical PDT protocol with no unexpected adverse effects reported."( Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.
Campbell, S; Curnow, A; Pye, A, 2008
)
0.35
"S-53482, 7-fluoro-6-[(3,4,5,6-tetrahydro)phthalimido]-4-(2-propynyl)-1,4-benzoxazin-3(2H)-one (flumioxazin), is an N-phenylimide herbicide and developmentally toxic to rats, but not to rabbits."( Close link between protoporphyrin IX accumulation and developmental toxicity induced by N-phenylimide herbicides in rats.
Fantel, AG; Kato, T; Kawamura, S, 2014
)
0.73
"The developmentally toxic compounds caused PPIX accumulation in embryos."( Close link between protoporphyrin IX accumulation and developmental toxicity induced by N-phenylimide herbicides in rats.
Fantel, AG; Kato, T; Kawamura, S, 2014
)
0.73
" Moreover, this therapeutic combination of agents is safe and does not weaken the healing of the sutured enterotomy site."( Prevention of adhesions post-abdominal surgery: Assessing the safety and efficacy of Chitogel with Deferiprone in a rat model.
Bassiouni, A; Bennett, C; Cooksley, C; Finnie, J; Jones, CF; Maddern, G; Moratti, S; Psaltis, AJ; Quarrington, RD; Trochsler, M; Vediappan, RS; Vreugde, S; Wormald, PJ, 2021
)
0.62
" Digestibility and proteomic evaluations were conducted to determine whether any potentially allergenic or toxic proteins occurred as the result of the mutation process."( Evaluation of the genotoxic potential of protoporphyrin IX and the safety of a protoporphyrin IX-rich algal biomass.
Béres, E; Endres, JR; Glávits, R; Goodman, RE; Hirka, G; Lu, G; Moghadam Maragheh, N; Murbach, TS; Pasics Szakonyiné, I; Vértesi, A, 2022
)
0.99

Pharmacokinetics

ExcerptReferenceRelevance
" ALA terminal half-life was approximately 45 min after intravenous or oral administration."( Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer.
Dalton, JT; Golub, AL; Marcus, SL; Meyer, MC; Straughn, A; Yates, CR; Yin, D, 2002
)
0.31
" The studies investigated the influence of patch application duration on PPIX-specific fluorescence and the pharmacokinetic properties of the 5-ALA patch."( Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses.
Ackermann, G; Birkel, M; Breuer, M; Ebeling, A; Fauteck, JD; Moor, AC; Ortland, C, 2008
)
0.35
"The 5-aminolevulinic acid (ALA)-derived endo-PpIX and exo-PpIX pharmacokinetic profiles were determined by the fluorescence intensity of cell extracts with a spectrophotometer based on a standard curve."( Comparison of pharmacokinetics, intracellular localizations and sonodynamic efficacy of endogenous and exogenous protoporphyrin IX in sarcoma 180 cells.
Liu, Q; Tong, W; Wang, P; Wang, X, 2010
)
0.57
" Lastly, cell uptake study and PET image-based pharmacokinetic analyses of the PPIX-PEG6-BBN analog were carried out in a human prostate cancer cell line, PC-3, which highly expresses the GRP receptor, and PC-3 tumor-bearing mice."( The synthesis of 64Cu-chelated porphyrin photosensitizers and their tumor-targeting peptide conjugates for the evaluation of target cell uptake and PET image-based pharmacokinetics of targeted photodynamic therapy agents.
Mukai, H; Wada, Y; Watanabe, Y, 2013
)
0.39
" PET image-based pharmacokinetic evaluation revealed that [(64)Cu]PPIX-PEG6-BBN analog and [(64)Cu]PPIX rapidly accumulate into the liver and kidney, circulate in blood for a long time compared with normal peptides, and distribute at a low level in the tumor."( The synthesis of 64Cu-chelated porphyrin photosensitizers and their tumor-targeting peptide conjugates for the evaluation of target cell uptake and PET image-based pharmacokinetics of targeted photodynamic therapy agents.
Mukai, H; Wada, Y; Watanabe, Y, 2013
)
0.39
" The clearance half-life of EDTA-induced PpIX was 4-7 times longer than that of PpIX after application of ALA."( Clearance mechanism of protoporphyrin IX from mouse skin after application of 5-aminolevulinic acid.
Iani, V; Juzeniene, A; Moan, J, 2013
)
0.7

Compound-Compound Interactions

ExcerptReferenceRelevance
" We have investigated the effect of 5-ALA mediated PDT in combination with gamma-irradiation on the colony forming ability of several human head and neck tumour cell lines."( Effect of photodynamic therapy in combination with ionizing radiation on human squamous cell carcinoma cell lines of the head and neck.
Allman, R; Cowburn, P; Mason, M, 2000
)
0.31
"Fluorescence spectroscopy combined with 5-aminolevulinic acid-induced protoporphyrin IX was found as a valuable tool in the diagnosis of oral premalignancy."( Fluorescence spectroscopy combined with 5-aminolevulinic acid-induced protoporphyrin IX fluorescence in detecting oral premalignancy.
El-Maaytah, M; Hopper, C; Jerjes, W; Khalil, HS; MacRobert, AJ; Salih, V; Sharwani, A, 2006
)
0.8
" Searching for new approaches, we tested a known inducer of cellular differentiation, methotrexate (MTX), in combination with ALA-PDT in LNCaP cells."( Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells.
Anand, S; Chang, Y; Hasan, T; Mai, Z; Maytin, EV; Ortel, BJ; Sinha, AK, 2006
)
0.33
"FH detection combined with HPV screening is efficient in the diagnosis of cervical cancer and precancerous lesion, which is better than single use of FH detection."( The role of FH detection combined with HPV screening on the diagnostic significance of cervical cancer and precancerous lesions.
Chen, HY; Hu, YJ; Ma, LH; Wang, Y; Zhang, HP; Zhu, B, 2018
)
0.48
"Comparison of the fluorescence intensity caused by the accumulation of PpIX in endometrial cancer xenografts in nude mice after low-dose 5-Aminolevulinic acid (ALA) injection combined with siRNA transfection was mediated by ultrasound microbubbles and polyethyleneimine (PEI) to explore the feasibility of the ultrasound microbubble technique as transfection agents."( Comparative Study of the Effects of Ferrochelatase-siRNA Transfection Mediated by Ultrasound Microbubbles and Polyethyleneimine in Combination with Low-dose ALA to Enhance PpIX Accumulation in Human Endometrial Cancer Xenograft Nude Mice Models.
Chen, L; Gao, L; Gao, X; Huang, X; Li, N; Lin, S; Song, Y; Wang, X; Zhang, X, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
" Lipophilicity is one of the key parameters defining the bioavailability of a topically applied drug."( 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells.
Juillerat-Jeanneret, L; Lange, N; Uehlinger, P; van den Bergh, H; Wagnières, G; Zellweger, M, 2000
)
0.54
" The purpose of these studies was to examine the systemic pharmacokinetics and elimination of ALA, the bioavailability of ALA after oral and intravesical doses, and the factors that affect ALA concentrations in the bladder during intravesical treatment."( Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer.
Dalton, JT; Golub, AL; Marcus, SL; Meyer, MC; Straughn, A; Yates, CR; Yin, D, 2002
)
0.31
" At around 30 degrees C PpIX fluorescence appears later after application of ALA-ester derivatives (14-20 min) than after application of ALA (8 min), indicating differences in their bioavailability (delayed penetration through the stratum corneum, cellular uptake, conversion to ALA, PpIX production) in mouse skin in vivo."( Temperature effect on accumulation of protoporphyrin IX after topical application of 5-aminolevulinic acid and its methylester and hexylester derivatives in normal mouse skin.
Iani, V; Juzenas, P; Juzeniene, A; Kaalhus, O; Moan, J, 2002
)
0.59
" However, in the case of deep, nodular-ulcerative lesions, the complete response rates are lower, possibly related to a lower bioavailability of PpIX."( Comparison of ALA- and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma.
Ballini, JP; Dögnitz, N; Gabrecht, T; Lange, N; Salomon, D; van den Bergh, H; Wagnières, G; Zellweger, M, 2008
)
0.35
" eEF1A1 was found to enrich ALA-induced PpIX in cells by competitively blocking the downstream bioavailability of PpIX."( eEF1A1 binds and enriches protoporphyrin IX in cancer cells in 5-aminolevulinic acid based photodynamic therapy.
Cui, X; Fan, Z; He, H; Li, B; Liu, W; Wei, D; Wei, X; Ye, H; Zhu, N, 2016
)
0.73
" The second is related to the relatively poor understanding of the pathways by which polymeric micelles improve the bioavailability of the payload by mucosal routes (e."( Protoporphyrin IX-modified chitosan-g-oligo(NiPAAm) polymeric micelles: from physical stabilization to permeability characterization in vitro.
Schlachet, I; Sosnik, A, 2016
)
1.88
" However, chemical instability, low bioavailability and poor pharmacokinetic profile limit systemic efficacy of 5-ALA."( Activity of phosphatase-sensitive 5-aminolevulinic acid prodrugs in cancer cell lines.
Allémann, E; Babič, A; Herceg, V; Lange, N, 2017
)
0.46

Dosage Studied

Protoporphyrin IX synthesis and photobleaching kinetics allow monitoring clinical PDT. It allows individual-based PDT dosing and improvement of clinical treatment protocols.

ExcerptRelevanceReference
" The dose-response relationship between this enzyme and lead concentrations was roughly linear for the workers with greater than 40 micrograms of lead per 100 g of blood."( Oxygen toxicity related to exposure to lead.
Abdalla, DS; Arcuri, AS; Bechara, EJ; Monteiro, HP, 1985
)
0.27
" Dose-response studies were conducted for 100 to 400 mg/ml 5-aminolevulinic acid."( Photodynamic destruction of endometrial tissue with topical 5-aminolevulinic acid in rats and rabbits.
Berns, MW; Krasieva, T; Schell, M; Tadir, Y; Tromberg, BJ; Wyss, MT; Wyss, P, 1994
)
0.29
" The intensity of fluorescence varied with the dosage and route of administration of 5-aminolevulinic acid."( Fluorescence and photosensitization of experimental endometriosis in the rat after systemic 5-aminolevulinic acid administration: a potential new approach to the diagnosis and treatment of endometriosis.
Kennedy, JC; Reid, RL; Van Dijk-Smith, JP; Van Vugt, DA; Yang, JZ, 1996
)
0.29
"Photodynamic therapy (PDT) with topical 5-aminolevulinic acid (ALA) is increasingly employed for skin cancer, yet ALA dosing is crude."( Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin.
Anderson, RR; Kollias, N; Rhodes, LE; Tsoukas, MM, 1997
)
0.3
"To determine the in vivo dose-response relation between administered 5-aminolevulinic acid (ALA) and the concentration of protoporphyrin IX (PpIX) produced in rat uterine tissue, to determine the effect of estrogen on ALA-induced PpIX production in the rat endometrium and myometrium, and to determine the selectivity of ALA-induced PpIX production in uterine tissue."( Effect of 5-aminolevulinic acid dose and estrogen on protoporphyrin IX concentrations in the rat uterus.
Pottier, RH; Reid, RL; Roy, BN; Van Vugt, DA; Weagle, GE,
)
0.59
"An in vivo dose-response relation was demonstrated between ALA and uterine production of PpIX, with maximum PpIX concentrations occurring after 25 mg of intrauterine ALA."( Effect of 5-aminolevulinic acid dose and estrogen on protoporphyrin IX concentrations in the rat uterus.
Pottier, RH; Reid, RL; Roy, BN; Van Vugt, DA; Weagle, GE,
)
0.38
" This study compares bolus with fractionated ALA dosing in order to determine whether one of these methods results in a higher tissue concentration of PP."( Effects of fractionated 5-aminolevulinic acid administration on tissue levels of protoporphyrin in vivo.
Fromm, D; Herman, MA; Kessel, D; Luo, Y; Patacsil, V; Webber, J, 1997
)
0.3
" A dose-response relationship was observed between 10 and 25 mg of ALA and endometrial PpIX concentrations."( Effect of continuous and multiple doses of 5-aminolevulinic acid on protoporphyrin IX concentrations in the rat uterus.
Pottier, RH; Reid, RL; Roy, BN; Van Vugt, DA; Weagle, GE, 1997
)
0.53
" The different parameters involved in this photodynamic effect are reported, namely delta-ala concentration and loading time, light dosage and the influence of intracellular and medium-excreted porphyrins."( Photodynamic DNA damage mediated by delta-aminolevulinic acid-induced porphyrins.
Dubois, J; Duez, P; Hanocq, M, 2001
)
0.31
" It allows quasiquantitative testing of different protoporphyrin IX precursors with respect to dose-response curves and pharmacokinetics, as well as the evaluation of different incubation conditions and/or different drug formulations."( Routine experimental system for defining conditions used in photodynamic therapy and fluorescence photodetection of (non-) neoplastic epithelia.
Etter, AL; Gerber, P; Jichlinski, P; Kucera, P; Lange, N; Marti, A; van Den Bergh, H; Vaucher, L, 2001
)
0.56
" In rats dosed with 5 mg As(III)/kg, the increases (expressed as % of the control values) of protoporphyrin IX in the blood were in the order: sodium arsenite (144%) > sodium arsenate (125%) > calcium arsenite (123%) > calcium arsenate."( Porphyrin profiles in blood and urine as a biomarker for exposure to various arsenic species.
Moore, MR; Ng, JC; Qi, L, 2002
)
0.53
" Although different formulations containing variable amounts of ALA have been applied in PDT, the dose-response relationships between transdermal ALA delivery and cutaneous protoporphyrin IX (PpIX) accumulation have not been studied."( In vitro/in vivo correlations between transdermal delivery of 5-aminolaevulinic acid and cutaneous protoporphyrin IX accumulation and effect of formulation.
Chen, IH; Lo, YL; Tsai, JC; Wong, TW, 2002
)
0.72
"Knowledge of the dose-response relationships and the effect of formulation is important for designing optimal formulations and treatment schedules for topical ALA-PDT."( In vitro/in vivo correlations between transdermal delivery of 5-aminolaevulinic acid and cutaneous protoporphyrin IX accumulation and effect of formulation.
Chen, IH; Lo, YL; Tsai, JC; Wong, TW, 2002
)
0.53
"It will be the aim of further investigations to verify the optimal time of incubation and dosing of systemical 5-ALA application to enhance fluorescence contrasts and set the basis for fluorescence guided resections."( [Fluorescence staining of oral and laryngeal cancer after application of 5-aminolevulinic acid].
Baumgartner, R; Betz, CS; Heinrich, P; Janda, P; Leunig, A, 2002
)
0.31
" More studies with higher patient numbers are necessary to evaluate optimal dosage and excitation conditions to detect tumor-bearing nodes in vivo."( Fluorescence diagnosis: a novel method to guide radical inguinal lymph node dissection in penile cancer.
Frimberger, D; Hofstetter, A; Hungerhuber, E; Linke, R; Meissner, H; Schmeller, N; Schneede, P; Stepp, H; Waidelich, R; Zaak, D, 2004
)
0.32
" The aim of this study was to establish the optimum dosage regime for ALA-PDT for Barrett's esophagus."( Comparison of high- vs low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett's esophagus.
Ackroyd, R; Brown, NJ; Brown, SB; Kelty, CJ; Reed, MW, 2004
)
0.32
" There was no significant difference in response between dosing 4 or 6 h prior to PDT."( Comparison of high- vs low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett's esophagus.
Ackroyd, R; Brown, NJ; Brown, SB; Kelty, CJ; Reed, MW, 2004
)
0.32
" The proportion of dead cells increased with increases in the dosage of light."( Massive apoptotic cell death of human glioma cells via a mitochondrial pathway following 5-aminolevulinic acid-mediated photodynamic therapy.
Inoue, H; Kajimoto, Y; Kuroiwa, T; Miyatake, S; Miyoshi, N; Ogawa, N; Otsuki, Y; Shibata, MA, 2007
)
0.34
" We have used gene dosage analysis by quantitative PCR to identify large deletions of the FECH gene in 19 (58%) of 33 unrelated UK patients with EPP in whom mutations could not be detected by sequencing."( Gene dosage analysis identifies large deletions of the FECH gene in 10% of families with erythropoietic protoporphyria.
Anstey, AV; Badminton, MN; Elder, GH; Holme, SA; Mason, NG; Whatley, SD, 2007
)
0.34
" Although PDT induced both apoptosis and necrosis, the ratio of apoptotic cells increased with light dosage or intracellular PpIX concentration."( Apoptosis of vascular smooth muscle cells induced by photodynamic therapy with protoporphyrin IX.
Cao, W; Cheng, J; Li, Q; Li, Z; Liang, H; Peng, C; Shi, S; Tian, Y; Zhang, Z, 2010
)
0.59
" Metronomic dosing in PDT is proposed by analogy and the rationale is as a means to improve the tumor-specific response through cell death by apoptosis."( Metronomic PDT and cell death pathways.
Alqawi, O; Espiritu, M; Singh, G, 2010
)
0.36
" A novel dosing approach was introduced in that we used a photobleaching percentage instead of a preset fluence."( Fractionated illumination at low fluence rate photodynamic therapy in mice.
De Bruijn, HS; De Haas, ER; Middelburg, TA; Neumann, HA; Robinson, DJ; Sterenborg, HJ; Van Der Ploeg-van den Heuvel, A; Van Zaane, F,
)
0.13
" Protoporphyrin IX synthesis and photobleaching kinetics allow monitoring clinical PDT which facilitates individual-based PDT dosing and improvement of clinical treatment protocols."( Correction for tissue optical properties enables quantitative skin fluorescence measurements using multi-diameter single fiber reflectance spectroscopy.
Amelink, A; Hoy, CL; Middelburg, TA; Neumann, HA; Robinson, DJ, 2015
)
1.33
" They revealed a different fluorescence kinetics and dose-response curves for the different types of 5-ALA prodrugs."( Activity of phosphatase-sensitive 5-aminolevulinic acid prodrugs in cancer cell lines.
Allémann, E; Babič, A; Herceg, V; Lange, N, 2017
)
0.46
" Herein, we performed animal and human studies to investigate whether 5-ALA dosed glioma cells, in vitro and in vivo, release PpIX positive EVs in circulation which can be captured and analyzed."( Characterization of plasma-derived protoporphyrin-IX-positive extracellular vesicles following 5-ALA use in patients with malignant glioma.
Ayinon, C; Balaj, L; Carter, BS; Charest, A; Delcuze, B; Ghiran, I; Hochberg, FH; Jones, PS; Lansbury, E; Mordecai, S; Small, JL; Tigges, J; Yekula, A, 2019
)
0.51
" A low dosage of loaded DTX in FA-CD@PP-CpG can promote infiltration of CTLs to improve efficacy of anti-PD-L1 antibody (aPD-L1), suppress MDSCs, and effectively polarize MDSCs toward M1 phenotype to reduce tumor burden, further to enhance the antitumor efficacy."( Tumor-Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel-Enhanced Immunotherapy with Polarization toward M1-Type Macrophages on Triple Negative Breast Cancers.
Chen, L; Dong, C; Han, Y; Hu, X; Liang, S; Lin, Y; Liu, J; Lu, Y; Shi, S; Wang, C; Yao, T; Zhou, L, 2019
)
0.51
" No difference was found when comparing the fluorescence between primary grade I and II meningiomas after any 5-ALA dosage (p > ."( 5-ALA kinetics in meningiomas: analysis of tumor fluorescence and PpIX metabolism in vitro and comparative analyses with high-grade gliomas.
Brokinkel, B; Bunk, EC; Senner, V; Stummer, W; Wagner, A, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (8)

PathwayProteinsCompounds
Metabolism14961108
Porphyrin metabolism2344
Heme biosynthesis1530
Porphyrin_metabolism ( Porphyrin metabolism )716
HMOX1 pathway (COVID-19 Disease Map)3630
heme biosynthesis from uroporphyrinogen-III II012
Biochemical pathways: part I0466
Heme synthesis324

Protein Targets (79)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency7.50800.003245.467312,589.2998AID1705; AID2517; AID2572
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency5.14040.004023.8416100.0000AID485290; AID489007
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency11.19360.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency7.89830.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency7.89830.025120.237639.8107AID886; AID893
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency4.46680.631035.7641100.0000AID504339
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency9.43320.125919.1169125.8920AID2353; AID2549
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID2323
Chain A, CruzipainTrypanosoma cruziPotency19.95260.002014.677939.8107AID1476
thioredoxin reductaseRattus norvegicus (Norway rat)Potency25.07220.100020.879379.4328AID488773; AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency12.92440.012610.691788.5700AID887
WRNHomo sapiens (human)Potency11.22020.168331.2583100.0000AID651768
USP1 protein, partialHomo sapiens (human)Potency44.96470.031637.5844354.8130AID504865; AID743255
NFKB1 protein, partialHomo sapiens (human)Potency0.31620.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency4.06770.35487.935539.8107AID624146; AID624170
TDP1 proteinHomo sapiens (human)Potency19.98840.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency15.03280.180013.557439.8107AID1460; AID1468
Smad3Homo sapiens (human)Potency10.00000.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency4.46680.707912.194339.8107AID720542
regulator of G-protein signaling 4Homo sapiens (human)Potency9.46620.531815.435837.6858AID504845
isocitrate dehydrogenase 1, partialHomo sapiens (human)Potency28.18386.309627.099079.4328AID602179
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency12.96140.001530.607315,848.9004AID1224819; AID1224820; AID1224821
arylsulfatase AHomo sapiens (human)Potency3.38081.069113.955137.9330AID720538
pyruvate kinaseLeishmania mexicana mexicanaPotency19.95260.398113.744731.6228AID945; AID959
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.65830.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency25.11890.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency2.51190.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency6.30960.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency19.95260.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency18.31740.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency0.21190.006026.168889.1251AID488953
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency14.43930.010039.53711,122.0200AID1469; AID1479
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency15.84893.548119.542744.6684AID743266
importin subunit beta-1 isoform 1Homo sapiens (human)Potency31.62285.804836.130665.1308AID540263
DNA polymerase betaHomo sapiens (human)Potency1.41250.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency16.10570.039816.784239.8107AID1454; AID995
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency26.12160.00669.809418.4927AID1347050
flap endonuclease 1Homo sapiens (human)Potency32.55940.133725.412989.1251AID588795; AID720498
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency14.68920.65619.452025.1189AID463106
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency13.37140.168316.404067.0158AID720504
snurportin-1Homo sapiens (human)Potency31.62285.804836.130665.1308AID540263
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency19.95260.010323.856763.0957AID2662
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency22.63480.425612.059128.1838AID504536; AID504891
tumor susceptibility gene 101 proteinHomo sapiens (human)Potency79.43280.129810.833132.6090AID485342
DNA polymerase eta isoform 1Homo sapiens (human)Potency1.82500.100028.9256213.3130AID588591; AID720502
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency14.42140.050127.073689.1251AID588590; AID720496
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency19.95260.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency14.58100.004611.374133.4983AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency18.10080.031622.3146100.0000AID588579
M-phase phosphoprotein 8Homo sapiens (human)Potency14.25980.177824.735279.4328AID488949
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency11.22020.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency10.00000.891312.067628.1838AID1487
chaperonin GroELMethanococcus maripaludis S2Potency31.622831.622831.622831.6228AID488978
neuropeptide S receptor isoform AHomo sapiens (human)Potency10.00000.015812.3113615.5000AID1461
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency17.90080.316212.765731.6228AID881
Glutamate receptor 1Rattus norvegicus (Norway rat)Potency11.29470.01418.602439.8107AID2572
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency11.29470.001551.739315,848.9004AID2572
Glutamate receptor 3Rattus norvegicus (Norway rat)Potency11.29470.01418.602439.8107AID2572
Glutamate receptor 4Rattus norvegicus (Norway rat)Potency11.29470.01418.602439.8107AID2572
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.93310.00638.235039.8107AID881; AID883
Single-stranded DNA cytosine deaminaseHomo sapiens (human)Potency53.342728.183860.145389.1251AID1347427; AID1347430
phosphoglycerate kinaseTrypanosoma brucei brucei TREU927Potency5.11550.07578.474229.0628AID602233; AID686980
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency19.01150.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, RNA-directed RNA polymerase NS5Dengue virus 2 16681-PDK53IC50 (µMol)34.59002.370054.1398100.0000AID588689
SUMO-1Homo sapiens (human)IC50 (µMol)34.20500.64707.494715.9000AID624382; AID624383
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)23.00000.00402.92669.9600AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)23.00000.00022.45859.9600AID1805801
60 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)4.90000.17004.559010.0000AID1594139
10 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)4.90000.17004.559010.0000AID1594139
Exoribonuclease H Human immunodeficiency virus 2IC50 (µMol)500.00000.00050.01520.0300AID161864
Thiosulfate sulfurtransferaseHomo sapiens (human)IC50 (µMol)100.00000.06003.96319.7000AID1594135
60 kDa chaperonin Escherichia coliIC50 (µMol)3.70000.03903.55529.8000AID1594140; AID1594141
Protease Human immunodeficiency virus 1IC50 (µMol)250.00000.00010.22487.3200AID162042; AID162045
10 kDa chaperonin Escherichia coliIC50 (µMol)3.70000.03903.55529.8000AID1594140; AID1594141
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
POsterior SegregationCaenorhabditis elegansEC50 (µMol)9.94902.201047.1808186.6810AID1964
Sodium-dependent noradrenaline transporter Homo sapiens (human)EC50 (µMol)8.88700.082031.0243168.9080AID1960
Coproheme decarboxylaseStaphylococcus aureus RF122Kd2.21002.21002.21002.2100AID1802378
Zinc finger protein mex-5Caenorhabditis elegansEC50 (µMol)8.88700.082033.5679168.9080AID1960
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (88)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein folding60 kDa chaperoninEscherichia coli K-12
response to radiation60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
virion assembly60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
protein refolding60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
adhesion of symbiont to host60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell60 kDa heat shock protein, mitochondrialHomo sapiens (human)
'de novo' protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to cold60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interferon-alpha production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-10 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-12 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-6 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein refolding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell proliferation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of macrophage activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isotype switching to IgG isotypes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein stabilization60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone-mediated protein complex assembly60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein maturation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
biological process involved in interaction with symbiont60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cellular response to interleukin-760 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein import into mitochondrial intermembrane space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial unfolded protein response60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apoptotic mitochondrial changes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
osteoblast differentiation10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process10 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein10 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone cofactor-dependent protein refolding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
sulfur amino acid catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
cyanate catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
epithelial cell differentiationThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA import into mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA transportThiosulfate sulfurtransferaseHomo sapiens (human)
mRNA processingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytidine deaminationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
somatic diversification of immunoglobulinsSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
somatic hypermutation of immunoglobulin genesSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
B cell differentiationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
regulation of nuclear cell cycle DNA replicationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
defense response to bacteriumSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
positive regulation of gene expression via chromosomal CpG island demethylationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
isotype switchingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cellular response to lipopolysaccharideSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
DNA cytosine deaminationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
DNA demethylationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytidine to uridine editingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
negative regulation of single stranded viral RNA replication via double stranded DNA intermediateSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
defense response to virusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (54)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
magnesium ion binding60 kDa chaperoninEscherichia coli K-12
protein binding60 kDa chaperoninEscherichia coli K-12
ATP binding60 kDa chaperoninEscherichia coli K-12
isomerase activity60 kDa chaperoninEscherichia coli K-12
ATP hydrolysis activity60 kDa chaperoninEscherichia coli K-12
identical protein binding60 kDa chaperoninEscherichia coli K-12
unfolded protein binding60 kDa chaperoninEscherichia coli K-12
ATP-dependent protein folding chaperone60 kDa chaperoninEscherichia coli K-12
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
lipopolysaccharide binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
p53 binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
DNA replication origin binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
single-stranded DNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
double-stranded RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
high-density lipoprotein particle binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isomerase activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP hydrolysis activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
enzyme binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ubiquitin protein ligase binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein A-I binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP-dependent protein folding chaperone60 kDa heat shock protein, mitochondrialHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
RNA binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding chaperone10 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
metal ion binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
thiosulfate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
5S rRNA bindingThiosulfate sulfurtransferaseHomo sapiens (human)
3-mercaptopyruvate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
cytidine deaminase activitySingle-stranded DNA cytosine deaminaseHomo sapiens (human)
protein bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
zinc ion bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
ubiquitin protein ligase bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
identical protein bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
RNA bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoplasm60 kDa chaperoninEscherichia coli K-12
cytosol60 kDa chaperoninEscherichia coli K-12
membrane60 kDa chaperoninEscherichia coli K-12
GroEL-GroES complex60 kDa chaperoninEscherichia coli K-12
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytoplasm60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrion60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
early endosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytosol60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
clathrin-coated pit60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cell surface60 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
coated vesicle60 kDa heat shock protein, mitochondrialHomo sapiens (human)
secretory granule60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm midpiece60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
migrasome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-containing complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
lipopolysaccharide receptor complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
mitochondrion10 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome10 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular spaceThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrial matrixThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
nucleusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytoplasmSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytosolSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
protein-containing complexSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
nucleusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytoplasmSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
P-bodySingle-stranded DNA cytosine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (71)

Assay IDTitleYearJournalArticle
AID1845443Photodynamic cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 3 hrs followed by fresh medium replacement and subsequent white LED irradiation measured after 24 hrs by MTT assay relative to control2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Porphyrin and phthalocyanine photosensitizers designed for targeted photodynamic therapy of colorectal cancer.
AID1845444Photodynamic cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 3 hrs followed by fresh medium replacement and subsequent blue LED irradiation measured after 24 hrs by MTT assay relative to control2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Porphyrin and phthalocyanine photosensitizers designed for targeted photodynamic therapy of colorectal cancer.
AID1845446Antitumor activity against human HT-29 cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 250 mg/kg, ip followed by LED irradiation with repeated compound irradiation for thrice upto 3 weeks relative to control2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Porphyrin and phthalocyanine photosensitizers designed for targeted photodynamic therapy of colorectal cancer.
AID1398507Phototoxicity in human HeLa cells assessed as reduction in cell viability preincubated for 1 hr followed by LED light irradiation for 15 mins measured after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
The design, synthesis, and evaluation of organic dithienopyrrole-based D-π-A dyes for use as sensitizers in photodynamic therapy.
AID1845445Photodynamic cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 3 hrs followed by fresh medium replacement and subsequent red LED irradiation measured after 24 hrs by MTT assay relative to control2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Porphyrin and phthalocyanine photosensitizers designed for targeted photodynamic therapy of colorectal cancer.
AID1398506Dark toxicity in human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
The design, synthesis, and evaluation of organic dithienopyrrole-based D-π-A dyes for use as sensitizers in photodynamic therapy.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1802378Fluorescence Titration Assay from Article 10.1074/jbc.M112.442335: \\The chlorite dismutase (HemQ) from Staphylococcus aureus has a redox-sensitive heme and is associated with the small colony variant phenotype.\\2013The Journal of biological chemistry, Aug-09, Volume: 288, Issue:32
The chlorite dismutase (HemQ) from Staphylococcus aureus has a redox-sensitive heme and is associated with the small colony variant phenotype.
AID1802329Tryptophan Fluorescence Assay from Article 10.1021/acs.biochem.6b01019: \\Tryptophan-Rich Sensory Protein/Translocator Protein (TSPO) from Cyanobacterium Fremyella diplosiphon Binds a Broad Range of Functionally Relevant Tetrapyrroles.\\2017Biochemistry, Jan-10, Volume: 56, Issue:1
Tryptophan-Rich Sensory Protein/Translocator Protein (TSPO) from Cyanobacterium Fremyella diplosiphon Binds a Broad Range of Functionally Relevant Tetrapyrroles.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1594143Selectivity index, ratio of IC50 for inhibition of native rhodanese (unknown origin) to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reducti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594134Inhibition of native soluble pig heart MDH assessed as reduction in MDH enzyme activity using sodium mesoxalate as substrate and NADH by malachite green dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594138Selectivity index, ratio of IC50 for inhibition of native soluble pig heart MDH to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction i2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594140Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594135Inhibition of native rhodanese (unknown origin) assessed as reduction in rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1550870Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and subsequent 3 mW/cm2 UVA irradiation for 20 mins measured 48 hrs post irradiation by CCK8 assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594142Selectivity index, ratio of IC50 for inhibition of native rhodanese (unknown origin) to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduct2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594141Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594139Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594137Inhibition of ATPase activity of Escherichia coli GroEL expressed in Escherichia coliDH5alpha incubated for 60 mins using ATP by spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594136Selectivity index, ratio of IC50 for inhibition of native soluble pig heart MDH to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1070911Antimutagenic activity against aflatoxin B1-induced Salmonella typhimurium TA102 mutagenesis preincubated at 0.5 umol/plate for 25 mins by Ames test in presence of S9 liver homogenate relative to control2013Journal of natural products, Oct-25, Volume: 76, Issue:10
Bilirubin and related tetrapyrroles inhibit food-borne mutagenesis: a mechanism for antigenotoxic action against a model epoxide.
AID162045Inhibition of HIV-1 protease in 10% fetal calf serum(FCS)1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Specific inhibition of HIV-1 protease by boronated porphyrins.
AID1070903Antimutagenic activity against aflatoxin B1-induced Salmonella typhimurium TA98 mutagenesis assessed as reduction in His+ revertants after 48 hrs by microscopy in presence of S9 liver homogenate2013Journal of natural products, Oct-25, Volume: 76, Issue:10
Bilirubin and related tetrapyrroles inhibit food-borne mutagenesis: a mechanism for antigenotoxic action against a model epoxide.
AID1070904Antimutagenic activity against aflatoxin B1-induced Salmonella typhimurium TA102 mutagenesis assessed as reduction in His+ revertants after 48 hrs by microscopy in presence of S9 liver homogenate2013Journal of natural products, Oct-25, Volume: 76, Issue:10
Bilirubin and related tetrapyrroles inhibit food-borne mutagenesis: a mechanism for antigenotoxic action against a model epoxide.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1304420Induction of ROS generation in EtOH/H2O solution assessed as reduction in DPBF absorbance at 0.5 uM preincubated with compound followed by white light irradiation for 30 mins by UV-visible spectrometric analysis relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1070908Antimutagenic activity against PhIP-induced Salmonella typhimurium TA98 mutagenesis preincubated at 0.5 umol/plate for 25 mins by Ames test in presence of S9 liver homogenate relative to control2013Journal of natural products, Oct-25, Volume: 76, Issue:10
Bilirubin and related tetrapyrroles inhibit food-borne mutagenesis: a mechanism for antigenotoxic action against a model epoxide.
AID161864Inhibition of HIV-2 protease in 5%DMSO1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Specific inhibition of HIV-1 protease by boronated porphyrins.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID162042Inhibition of HIV-1 protease in 5%DMSO1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Specific inhibition of HIV-1 protease by boronated porphyrins.
AID106898Inhibition of HIV-1 P24 production.1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1.
AID1070910Antimutagenic activity against aflatoxin B1-induced Salmonella typhimurium TA98 mutagenesis preincubated at 0.5 umol/plate for 25 mins by Ames test in presence of S9 liver homogenate relative to control2013Journal of natural products, Oct-25, Volume: 76, Issue:10
Bilirubin and related tetrapyrroles inhibit food-borne mutagenesis: a mechanism for antigenotoxic action against a model epoxide.
AID1304421Induction of ROS generation in EtOH/H2O solution assessed as reduction in DPBF absorbance at 0.5 uM preincubated with compound followed by ultrasound irradiation for 30 mins by UV-visible spectrometric analysis relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID104239Inhibition of HIV-1 P24 production.1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1.
AID46493Cytotoxicity on COS A6 cells in the absence of 10% fetal calf serum(FCS)1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Specific inhibition of HIV-1 protease by boronated porphyrins.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1583165Photo-activated cytotoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 4 hrs followed by compound washout and subsequent 3.3 mW cm'-2 light irradiation for 24 mins measured after 48 hrs by MTT assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Rose Bengal-Amphiphilic Peptide Conjugate for Enhanced Photodynamic Therapy of Malignant Melanoma.
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,030)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990113 (5.57)18.7374
1990's331 (16.31)18.2507
2000's601 (29.61)29.6817
2010's829 (40.84)24.3611
2020's156 (7.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 63.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index63.77 (24.57)
Research Supply Index7.70 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index111.07 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (63.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials76 (3.58%)5.53%
Reviews95 (4.47%)6.00%
Case Studies35 (1.65%)4.05%
Observational2 (0.09%)0.25%
Other1,915 (90.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Portable Measurement of Protoporphyrin IX in the Skin [NCT04223570]218 participants (Anticipated)Observational2022-12-01Enrolling by invitation
Non-invasive Optical Detection of Iron Deficiency in Children- Evaluation of a Fiber Optic Tissue Fluorescence Measurement to Determine the Erythrocyte Zinc Protoporphyrin-IX/Heme Ratio [NCT02701309]100 participants (Actual)Observational2016-04-30Completed
Efficacy of Based MRI Contrast Media Against Covid-19 [NCT04371822]Phase 156 participants (Anticipated)Interventional2020-08-31Not yet recruiting
Non-invasive Diagnostics of Iron Deficiency in Surgical Patients by Measuring Zinc Protoporphyrin-IX [NCT03071497]300 participants (Actual)Observational2017-03-03Completed
Insufficient Oxygenation in Septic Patients [NCT03842722]100 participants (Anticipated)Observational2019-02-13Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]